1e
19
1
49
2
2
18
1b
1d
18
41
72
1d
2 29
1d
25
Angela M DeMichele, MD, MSCE, FASCO
78
72
Mariann T. and Robert J. MacDonald Professor in Breast Cancer Care Excellence
28
95
3
5f
Senior Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
8b
Co-Leader, Breast Cancer Program, Abramson Cancer Center, University of Pennsylvania
b2
Co-Director, 2-PREVENT Breast Cancer Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania
b1
Director of Clinical/Translational Research in Solid Oncology, Division of Hematology/Oncology, University of Pennsylvania
11
Department: Medicine
4
1
b
1d
46
Contact information
4e
4
3
3
3
2
29
4
b
1f
4e
Division of Hematology Oncology
2d Perelman Center for Advanced Medicine
22 10th Floor, South Pavilion
16 Office #10-153
3e 3400 Civic Center Boulevard
Philadelphia, PA 19104
26
2d Perelman Center for Advanced Medicine
22 10th Floor, South Pavilion
16 Office #10-153
3e 3400 Civic Center Boulevard
Philadelphia, PA 19104
2e
Office: 215-349-5730
32 Fax: 215-615-3349
24
9f
12
32 Fax: 215-615-3349
24
13
Education:
21 9 B.A. 19 (Biochemistry) c
29 Brown University, 1988.
21 9 M.D. 15 (Medicine) c
41 Washington University School of Medicine, 1991.
21 d M.S.C.E. 22 (Clinical Epidemiology) c
47 University of Pennsylvania, School of Medicine, 2001.
c
3
3
3
3
8b
Permanent link21 9 B.A. 19 (Biochemistry) c
29 Brown University, 1988.
21 9 M.D. 15 (Medicine) c
41 Washington University School of Medicine, 1991.
21 d M.S.C.E. 22 (Clinical Epidemiology) c
47 University of Pennsylvania, School of Medicine, 2001.
c
2 29
21
1e
1d
24
5e
65
1a 29
27
Description of Research Expertise
99 breast cancer, biomarkers, clinical trials, pharmacogenetics, cytokines, host immunogenetics, cancer survivorship, molecular epidemiology65
Description of Clinical Expertise
6e breast cancer, neoadjuvant therapy, menopausal symptoms related to cancer, cancer survivorship1a 29
23
18b Sun X, Ocampo AA, Hanna A, Taylor BC, Marshall JL, Steele JA, Axelrod ML, Wescott EC, Opalenik SR, DeMichele A, Esserman LJ, Liu MC, Nanda R, Wolf DM, Brown Swigart L, Hirst GL, van 't Veer LJ, Xu Y, Balko JM. : Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer 31 Sci Transl Med Apr 2026.
268 Hunter NB, Parsons HA, Cope L, Canzoniero JV, Navarro FCP, El-Refai S, Anampa JD, Sparano JA, Rimawi M, Storniolo AM, Mainor C, Nanda R, DeMichele A, Gupta GP, Stringer-Reasor EJ, Lynce F, Cobain EF, Puhalla S, Jankowitz R, Rexer B, Mayer I, Hwang ES, Blackwell K, El Ayass W, Lee Y, Tweed C, Wilkinson M, Pennisi A, Sun B, Wright P, Gralow JR, Chen R, Boyle SM, Stearns V, Wolff AC, Park BH. : The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease 30 J Clin Oncol. Mar 2026.
248 Metzger O, Mandrekar S, Goel S, Gligorov J, Lim E, Ciruelos E, Loibl S, Dockter T, Gonzàlez Farré X, Francis PA, Lynce F, Lanzillotti J, DuFrane C, Wall A, Strand C, Krop I, Vaz-Luis I, Tripathy D, Loi S, Prat A, Goetz M, Escrivá-de-Romaní S, Porter D, Spoenlein J, Stover DG, Sardesai S, Heudel P, Koehler M, Huang Bartlett C, Holynskyj A, Gopalakrishna P, Gauthier E, Delaloge S, Miller K, Winer EP, Gianni L, Partridge AH, DeMichele A, Carey LA.: Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer 2f N Engl J Med Jan 2026.
1dd Magbanua MJM, Manon NA, Wolf DM, Rivero-Hinojosa S, Ahmed Z, Sayaman RW, Tin A, Renner D, Kalashnikova E, Brown-Swigart L, Hirst GL, Yau C, Li W, Isaacs C, Shatsky RA, Clark AS, Zimmer A, Delson AL, Rodriguez A, Liu MC, Pohlmann PR, Esserman LJ, Rugo HS, DeMichele A, van 't Veer L. : Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors. Nat Commun Dec 2025.
240 Chislock EM, Pan TC, Pant D, Chen Y, Woodfield G, Graves J, Lawrence-Paul MR, Belka GK, Wang J, Bayne L, Blanchard T, Smith M, Ji X, Shih NNC, Soucier-Ernst D, Goodman N, Nivar I, Goodspeed B, DeLuca S, Ndicu J, Clark C, Langer M, William Stavropoulos S, DeMuth W, Morschauser A, Murphy W, Nayak A, Feldman M, Clark A, Yu L, Judge K, Bornheimer S, Pletcher CH Jr, Moore JS, DeMichele A, Chodosh LA. : DTC-Flow: a flow cytometry-based detection platform for characterizing bone marrow disseminated tumor cells in breast cancer 35 NPJ Breast Cancer Nov 2025.
1f5 Gerratana L, Reduzzi C, Ren Y, Jeselsohn R, Mahtani RL, Ma CX, DeMichele A, Meisel JL, Miller K, Abdou Y, Riley EC, Qamar R, Sharma P, Reid SA, Ko N, Liu Y, Gauthier E, Burstein HJ, DeMeo M, Tolaney SM, Regan MM, Cristofanilli M, Mayer EL.: Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study. Clin Cancer Res Nov 2025.
16c Thomas A, Rhoads A, Mayer EL, O'Reilly S, Harbeck N, Curigliano G, Zhou Y, Adam V, Chan N, Conway KM, Ignatiadis M, Kalinsky K, DeMichele A, Romitti PA. : Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010-2021. NPJ Breast Cancer Nov 2025.
1eb Hennessy, M. A., Gatsonis, C., Jacene, H., Connolly, R. M., Burnette, B. L., Stringer-Reasor, E. M., Romanoff, J., Taurone, A., O'Sullivan, C. C., Le-Petross, H. T., Stearns, V., Fowler, A. M., Tang, S., Sepulveda, K. A., DeMichele, A. M., Mankoff, D. A., Wolff, A. C. : EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial). Future Oncology Oct 2025.
1ff DeMichele, A., Clark, A. S., Shea, E., Bayne, E. J., Sterner, C. J., Rohn, K., Dwyer, S., Pan, T., Nivar, I., Chen, Y., Wileyto, P., Berry, L. R., Deluca, S., Savage, J., Makhlin, I., Pant, D. K., Martin, H., Egunsola, A., Mears, N., Goodspeed, B. L., Chislock, E. M., Graves, J., Wang, J., Shih, N., Belka, G. K., Berry, D., Nayak, A., Feldman, M., & Chodosh, L. A.: Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial 32 Nature Medicine Sep 2025.
2c
7
1d
1f
Selected Publications
268 Denkert C, Rachakonda S, Pehl A, Marmé F, Martin M, Karn T, Untch M, Bonnefoi H, Kim SB, Hirmas N, Bear H, Witkiewicz AK, Im SA, DeMichele A, Veer LV, McCarthy N, Stiewe T, Jank P, Gelmon KA, García-Sáenz JA, Westhoff C, Kelly CM, Reimer T, Olivé MM, Knudsen ES, van Mackelenbergh M, Rojo F, Frickel N, Fasching PA, Teply-Szymanski J, Toi M, Rugo HS, Gnant M, Makris A, Felder B, Nekljudova V, Loibl S.: Clinical and Molecular Evaluation of HER2-Low and Ultralow Breast Cancer in the PENELOPE-B Clinical Trial Cohort. Mod Pathol. Apr 2026.18b Sun X, Ocampo AA, Hanna A, Taylor BC, Marshall JL, Steele JA, Axelrod ML, Wescott EC, Opalenik SR, DeMichele A, Esserman LJ, Liu MC, Nanda R, Wolf DM, Brown Swigart L, Hirst GL, van 't Veer LJ, Xu Y, Balko JM. : Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer 31 Sci Transl Med Apr 2026.
268 Hunter NB, Parsons HA, Cope L, Canzoniero JV, Navarro FCP, El-Refai S, Anampa JD, Sparano JA, Rimawi M, Storniolo AM, Mainor C, Nanda R, DeMichele A, Gupta GP, Stringer-Reasor EJ, Lynce F, Cobain EF, Puhalla S, Jankowitz R, Rexer B, Mayer I, Hwang ES, Blackwell K, El Ayass W, Lee Y, Tweed C, Wilkinson M, Pennisi A, Sun B, Wright P, Gralow JR, Chen R, Boyle SM, Stearns V, Wolff AC, Park BH. : The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease 30 J Clin Oncol. Mar 2026.
248 Metzger O, Mandrekar S, Goel S, Gligorov J, Lim E, Ciruelos E, Loibl S, Dockter T, Gonzàlez Farré X, Francis PA, Lynce F, Lanzillotti J, DuFrane C, Wall A, Strand C, Krop I, Vaz-Luis I, Tripathy D, Loi S, Prat A, Goetz M, Escrivá-de-Romaní S, Porter D, Spoenlein J, Stover DG, Sardesai S, Heudel P, Koehler M, Huang Bartlett C, Holynskyj A, Gopalakrishna P, Gauthier E, Delaloge S, Miller K, Winer EP, Gianni L, Partridge AH, DeMichele A, Carey LA.: Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer 2f N Engl J Med Jan 2026.
1dd Magbanua MJM, Manon NA, Wolf DM, Rivero-Hinojosa S, Ahmed Z, Sayaman RW, Tin A, Renner D, Kalashnikova E, Brown-Swigart L, Hirst GL, Yau C, Li W, Isaacs C, Shatsky RA, Clark AS, Zimmer A, Delson AL, Rodriguez A, Liu MC, Pohlmann PR, Esserman LJ, Rugo HS, DeMichele A, van 't Veer L. : Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors. Nat Commun Dec 2025.
240 Chislock EM, Pan TC, Pant D, Chen Y, Woodfield G, Graves J, Lawrence-Paul MR, Belka GK, Wang J, Bayne L, Blanchard T, Smith M, Ji X, Shih NNC, Soucier-Ernst D, Goodman N, Nivar I, Goodspeed B, DeLuca S, Ndicu J, Clark C, Langer M, William Stavropoulos S, DeMuth W, Morschauser A, Murphy W, Nayak A, Feldman M, Clark A, Yu L, Judge K, Bornheimer S, Pletcher CH Jr, Moore JS, DeMichele A, Chodosh LA. : DTC-Flow: a flow cytometry-based detection platform for characterizing bone marrow disseminated tumor cells in breast cancer 35 NPJ Breast Cancer Nov 2025.
1f5 Gerratana L, Reduzzi C, Ren Y, Jeselsohn R, Mahtani RL, Ma CX, DeMichele A, Meisel JL, Miller K, Abdou Y, Riley EC, Qamar R, Sharma P, Reid SA, Ko N, Liu Y, Gauthier E, Burstein HJ, DeMeo M, Tolaney SM, Regan MM, Cristofanilli M, Mayer EL.: Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study. Clin Cancer Res Nov 2025.
16c Thomas A, Rhoads A, Mayer EL, O'Reilly S, Harbeck N, Curigliano G, Zhou Y, Adam V, Chan N, Conway KM, Ignatiadis M, Kalinsky K, DeMichele A, Romitti PA. : Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010-2021. NPJ Breast Cancer Nov 2025.
1eb Hennessy, M. A., Gatsonis, C., Jacene, H., Connolly, R. M., Burnette, B. L., Stringer-Reasor, E. M., Romanoff, J., Taurone, A., O'Sullivan, C. C., Le-Petross, H. T., Stearns, V., Fowler, A. M., Tang, S., Sepulveda, K. A., DeMichele, A. M., Mankoff, D. A., Wolff, A. C. : EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial). Future Oncology Oct 2025.
1ff DeMichele, A., Clark, A. S., Shea, E., Bayne, E. J., Sterner, C. J., Rohn, K., Dwyer, S., Pan, T., Nivar, I., Chen, Y., Wileyto, P., Berry, L. R., Deluca, S., Savage, J., Makhlin, I., Pant, D. K., Martin, H., Egunsola, A., Mears, N., Goodspeed, B. L., Chislock, E. M., Graves, J., Wang, J., Shih, N., Belka, G. K., Berry, D., Nayak, A., Feldman, M., & Chodosh, L. A.: Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial 32 Nature Medicine Sep 2025.
2c